Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03908125 · ClinicalTrials.gov registry record · NA
Post Approval Study of the Eversense® Continuous Glucose Monitoring
A NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, sponsored by Senseonics.
- Completed
- Registry status
- NA
- Development phase
- 273
- Enrollment target
- 17
- Study locations
NCT03908125 is a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus that has completed, run by Senseonics. The registered enrollment target is 273 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT03908125, a NA study of Diabetes Mellitus, Type 2 and Diabetes Mellitus, has completed, sponsored by Senseonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 273 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System
Conditions Studied
Interventions
- DEVICE Eversense® CGM System
Study Locations (17)
Texas
- Texas Diabetes and Endocrinology - Austin
- Clinical Research Solution, LLC - Cypress
- Javara, Inc - Houston
- Diabetes and Glandular Disease Clinic - San Antonio
- Consano Clinical Research, LLC - Shavano Park
North Carolina
- Physicians East - Greenville
- PMG Research of Wilmington, LLC - Wilmington
California
- Hoag Memorial Hospital Presbyterian/Mary Dick Allen Diabetes Center - Newport Beach
Colorado
- Denver Endocrinology, Diabetes & Thyroid Center - Englewood
Florida
- The Center for Diabetes and Endocrine Care - Fort Lauderdale
Georgia
- Atlanta Diabetes Associates - Atlanta
Maryland
- MODEL Clinical research - Baltimore
Michigan
- Metro Detroit Endocrinology Center - Dearborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2019-03-19 |
| Est. Completion | 2024-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03908125
The ClinicalTrials.gov registry entry for NCT03908125 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The listed sponsor is Senseonics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Eversense® CGM System is the first listed.
NCT03908125 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Texas, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT03908125 about?
NCT03908125 is a clinical study titled "Post Approval Study of the Eversense® Continuous Glucose Monitoring". A Post Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System over repeat insertion and removal cycles and to demonstrate the long-term safety of the Eversense® CGM System
What is the current status of trial NCT03908125?
This trial is currently completed. It is a NA study. The enrollment target is 273 participants. The study started on 2019-03-19. Estimated completion is 2024-02-01.
What conditions does trial NCT03908125 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT03908125?
The interventions under investigation include: Eversense® CGM System (DEVICE).
Who is sponsoring clinical trial NCT03908125?
This trial is sponsored by Senseonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03908125 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.